Literature DB >> 2668942

Ethnic distribution of amyloidosis: an autopsy study.

F S Buck1, M N Koss, A E Sherrod, A Wu, M Takahashi.   

Abstract

We examined the ethnic heritage of 467 patients with amyloidosis and related it to the type of amyloid (secondary versus other types) found among 52,370 autopsies at Los Angeles County-University of Southern California Medical Center. Classification of amyloidosis by type was accomplished by using the potassium permanganate Congo red staining method and a specific anti-AA antiserum, supplemented by the anatomical distribution of the amyloid in some instances. We discovered a statistically significant increase in amyloidosis among patients with hispanic surnames as compared with other Caucasians. The overall rate for Hispanics in our total autopsy population was 2.3% as compared with 0.6% for other Caucasians (P less than or equal to 0.001). The increase was mostly among those whose amyloid was negative to tests for secondary (AA) amyloidosis and not anatomically compatible with senile cardiac (senile systemic) amyloidosis. Hispanics accounted for 76% of these cases as compared with 18.5% for Caucasians (P less than or equal to 0.001). Our findings, along with previously published reports, suggest that the frequency of amyloidosis may vary significantly in different ethnic groups.

Entities:  

Mesh:

Year:  1989        PMID: 2668942

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

Review 1.  New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.

Authors:  Stefano Perlini; Roberta Mussinelli; Francesco Salinaro
Journal:  Curr Heart Fail Rep       Date:  2016-12

2.  Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies.

Authors:  Joel Buxbaum; Alice Alexander; James Koziol; Clement Tagoe; Ervin Fox; Dalane Kitzman
Journal:  Am Heart J       Date:  2010-05       Impact factor: 4.749

Review 3.  Transthyretin Cardiac Amyloidosis in Black Americans.

Authors:  Keyur B Shah; Anit K Mankad; Adam Castano; Olakunle O Akinboboye; Phillip B Duncan; Icilma V Fergus; Mathew S Maurer
Journal:  Circ Heart Fail       Date:  2016-06       Impact factor: 8.790

4.  Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center.

Authors:  Raymond C Givens; Chris Russo; Philip Green; Mathew S Maurer
Journal:  Aging health       Date:  2013-04-01

Review 5.  Mitral valve involvement as a predominant feature of cardiac amyloidosis.

Authors:  Girish Viswanathan; James Williams; Simon Slinn; Philip Campbell
Journal:  BMJ Case Rep       Date:  2010-10-10

Review 6.  [The various forms of left ventricular hypertrophy: diagnostic value of echocardiography].

Authors:  F Weidemann; S Störk; S Herrmann; G Ertl; M Niemann
Journal:  Herz       Date:  2011-12       Impact factor: 1.443

7.  Familial (ATTR) amyloidosis misdiagnosed as the primary (AL) variant: a case report.

Authors:  Philip B Dattilo
Journal:  Cases J       Date:  2009-12-09

8.  Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.

Authors:  Selma F Mohammed; Sultan A Mirzoyev; William D Edwards; Ahmet Dogan; Donna R Grogan; Shannon M Dunlay; Veronique L Roger; Morie A Gertz; Angela Dispenzieri; Steven R Zeldenrust; Margaret M Redfield
Journal:  JACC Heart Fail       Date:  2014-04       Impact factor: 12.035

Review 9.  Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.

Authors:  Joel N Buxbaum; Frederick L Ruberg
Journal:  Genet Med       Date:  2017-01-19       Impact factor: 8.822

10.  Prevalence and organ distribution of leukocyte chemotactic factor 2 amyloidosis (ALECT2) among decedents in New Mexico.

Authors:  Christopher P Larsen; Marjorie L Beggs; Jon D Wilson; Sarah L Lathrop
Journal:  Amyloid       Date:  2016-02-25       Impact factor: 7.141

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.